| Downgrades | Buy Neutral | X | ||
| Upgrades | Neutral Buy | X | ||
| Downgrades | Buy Neutral | X | ||
| Downgrades | Buy Neutral | X | ||
| Downgrades | Overweight Neutral | X | ||
| Reiterated | Buy | X | ||
|
$80 $190 |
||||
| Initiated | Buy | X | ||
| Reiterated | Buy | X | ||
|
$20 $66 |
||||
SAVA Cassava Sciences Inc
Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for nervous system disorders. Its lead therapeutic product candidate is PTI-125, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was founded in 1998 and is based in Austin, Texas.
